Test Catalog

Test Id : CYPAN

Cytokine Panel, Plasma

Useful For
Suggests clinical disorders or settings where the test may be helpful

Understanding the etiology of infectious or chronic inflammatory diseases, when used in conjunction with clinical information and other laboratory testing


Research studies in which an assessment of cytokine responses is needed

Method Name
A short description of the method used to perform the test

Bead-Based Multiplex Immunoassay

NY State Available
Indicates the status of NY State approval and if the test is orderable for NY State clients.


Reporting Name
Lists a shorter or abbreviated version of the Published Name for a test

Cytokine Panel, P

Lists additional common names for a test, as an aid in searching

Cytokine storm


Tumor necrosis factor alpha


Interferon Beta



Monocyte Chemoattractant Protein-1

Interleukin-1 beta


Interferon gamma


Macrophage Inflammatory Protein-1A

Granulocyte Macrophage Colony Stimulating Factor

CD25/IL-2 RA

Interleukin-2 Soluble Receptor Alpha

Interferon alpha-2a



Specimen Type
Describes the specimen type validated for testing

Plasma EDTA

Specimen Required
Defines the optimal specimen required to perform the test and the preferred volume to complete testing

Supplies: Sarstedt Aliquot Tube, 5 mL (T914)

Collection Container/Tube: Lavender-top (EDTA)

Submission Container/Tube: Plastic vial

Specimen Volume: 0.5 mL

Collection Instructions:

1. Immediately after specimen collection, place the tube on wet ice.

2. Centrifuge at 4 degrees C, 1500 x g for 10 minutes.

3.  Aliquot plasma into plastic vial.

4. Freeze specimen within 2 hours of collection.

Specimen Minimum Volume
Defines the amount of sample necessary to provide a clinically relevant result as determined by the Testing Laboratory

0.3 mL

Reject Due To
Identifies specimen types and conditions that may cause the specimen to be rejected

Gross hemolysis Reject
Gross lipemia Reject
Gross icterus Reject
Heat-treated specimen Reject

Specimen Stability Information
Provides a description of the temperatures required to transport a specimen to the performing laboratory, alternate acceptable temperatures are also included

Specimen Type Temperature Time Special Container
Plasma EDTA Frozen 21 days

Useful For
Suggests clinical disorders or settings where the test may be helpful

Understanding the etiology of infectious or chronic inflammatory diseases, when used in conjunction with clinical information and other laboratory testing


Research studies in which an assessment of cytokine responses is needed

Clinical Information
Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

Cytokines are important mediators of cell-to-cell communication within the innate and adaptive immune systems. The expression of most cytokines is highly regulated and generally occurs in response to foreign or self-antigenic stimulation. The functions of cytokines are extremely varied, with many cytokines also displaying pleiotropic effects, depending on their cellular target. Some cytokines, such as tumor necrosis factor (TNF), interleukin (IL)-1 beta, IL-6, interferon (IFN)-alpha and beta, IL-10, and IL-18 are particularly important in the innate immune response. For example, TNF, IL-1 beta, and IL-6 induce expression of acute phase proteins in the liver. TNF and IL-1 beta also lead to endothelial activation and are critical regulators of the hypothalamus, which can result in elevated body temperature. IL-6, in comparison, is a bridge to the adaptive immune response, by acting on B cells to induce proliferation. In contrast, IFN-alpha and IFN-beta (members of the type I IFN family) are key components of the innate immune response to viral infections. IFN-gamma, which is a type II IFN, has roles in both the innate and adaptive immune responses, including macrophage activation, induction of B-cell isotype switching, and T helper type 1 cell differentiation. Other cytokines, such as monocyte chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein-1alpha (MIP-1alpha), are categorized as chemokines because they function primarily to attract leukocytes to the site of inflammation. Further, some cytokines act on hematopoietic stem cells to induce differentiation of various leukocytes. For example, granulocyte-monocyte colony stimulating factor (GM-CSF) induces myeloid progenitor cells to differentiate into neutrophils and monocytes. Lastly, for some cytokines, soluble forms of the receptor can be found in the peripheral circulation. The IL-2 soluble receptor is produced from proteolytic cleavage of the membrane-bound receptor, which occurs during T-cell activation. As a group, cytokines and their receptors represent a highly complex and critical regulator of a normal immune response.

Reference Values
Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.

Tumor necrosis factor: <10.0 pg/mL

Interleukin (IL)-6: <5.0 pg/mL

Interferon (IFN)-beta: <20.0 pg/mL

IL-10: <7.0 pg/mL

Monocyte chemoattractant protein-1: < or =198 pg/mL

IL-1 beta: <20.0 pg/mL

IFN-gamma: <60.0 pg/mL

Macrophage inflammatory protein-1 alpha: <220 pg/mL

Granulocyte-monocyte colony stimulating factor: <15.0 pg/mL

IL-2 receptor alpha soluble: < or =959 pg/mL

IFN-alpha: <20.0 pg/mL

IL-18: < or =468 pg/mL

Provides information to assist in interpretation of the test results

Elevated cytokine concentrations could be consistent with the presence of infection or other inflammatory process.

Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

Results from cytokine testing should not be used to establish or exclude a specific diagnosis.


Cytokine testing should only be used in conjunction with clinical information and other laboratory testing as part of a patient’s overall assessment.


Normal concentrations of cytokines do not exclude the possibility of infection or other inflammatory condition.


Cytokine concentrations could be affected by immunomodulatory agents.

Clinical Reference
Recommendations for in-depth reading of a clinical nature

1. Bozza FA, Salluh JI, Japiassu AM, et al: Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis. Crit Care. 2007;11(2):R49. doi: 10.1186/cc5783

2. Milman N, Karsh J, Booth RA: Correlation of a multi-cytokine panel with clinical disease activity in patients with rheumatoid arthritis. Clin Biochem. 2010 Nov;43(16-17):1309-1314. doi: 10.1016/j.clinbiochem.2010.07.012

3. Teijara JR: Type I interferons in viral control and immune regulation. Curr Opin Virol. 2016 Feb;16:31-40. doi: 10.1016/j.coviro.2016.01.001

4. Tisoncki JR, Korth MJ, Simmons CP, Farrar J, Martin TR, Katze MG: Into the eye of the cytokine storm. Microbiol Mol Biol Rev. 2010 Mar;76(1):16-32. doi: 10.1128/MMBR.05015-11

5. Garcia Borrega J, Godel P, Ruger MA, et al: In the eye of the storm: Immune-mediated toxicities associated with CAR-T cell therapy. Hemasphere. 2019 Mar 29;3(2):e191. doi: 10.1097/HS9.0000000000000191

Method Description
Describes how the test is performed and provides a method-specific reference

Analyte-specific antibodies are pre-coated onto color-coded magnetic microparticles. Samples are diluted 1:2 in a mixing plate and then standards, samples, and microparticles are pipetted into wells and the immobilized antibodies capture the analytes of interest. Unbound substances are washed away while the magnetic microparticles are immobilized. Next, a biotinylated analyte specific antibody cocktail is added to each well. Following a wash to remove any unbound biotinylated antibody, streptavidin-phycoerythrin conjugate (Streptavidin-PE), is added to each well. After removal of unbound Streptavidin-PE and resuspension of the microparticles in buffer, the plate is analyzed using a Luminex FLEXMAP 3D analyzer. A charged-coupled device (CCD) camera captures an image of each well and data reduction is performed using the XPONENT software.(Unpublished Mayo method)

PDF Report
Indicates whether the report includes an additional document with charts, images or other enriched information


Day(s) Performed
Outlines the days the test is performed. This field reflects the day that the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time before the test is performed. Some tests are listed as continuously performed, which means that assays are performed multiple times during the day.


Report Available
The interval of time (receipt of sample at Mayo Clinic Laboratories to results available) taking into account standard setup days and weekends. The first day is the time that it typically takes for a result to be available. The last day is the time it might take, accounting for any necessary repeated testing.

2 to 8 days

Specimen Retention Time
Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded

14 days

Performing Laboratory Location
Indicates the location of the laboratory that performs the test


Several factors determine the fee charged to perform a test. Contact your U.S. or International Regional Manager for information about establishing a fee schedule or to learn more about resources to optimize test selection.

  • Authorized users can sign in to Test Prices for detailed fee information.
  • Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
  • Prospective clients should contact their Regional Manager. For assistance, contact Customer Service.

Test Classification
Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR) product.

This test was developed, and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information
Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Clinic Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.

CPT codes are provided by the performing laboratory.

83520 x 11


LOINC® Information
Provides guidance in determining the Logical Observation Identifiers Names and Codes (LOINC) values for the order and results codes of this test. LOINC values are provided by the performing laboratory.

Test Id Test Order Name Order LOINC Value
CYPAN Cytokine Panel, P 82335-1
Result Id Test Result Name Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
610307 TNF 3074-2
610308 IL-6 26881-3
610309 IFN-beta 97051-7
610310 IL-10 26848-2
610311 MCP-1 97052-5
610312 IL-1 beta 13629-1
610313 IFN-gamma 27415-9
610314 MIP-1 alpha 97053-3
610315 GM-CSF 97054-1
610316 IL-2 receptor alpha soluble 76039-7
610317 IFN-alpha 33820-2
610318 IL-18 33823-6

Test Setup Resources

Setup Files
Test setup information contains test file definition details to support order and result interfacing between Mayo Clinic Laboratories and your Laboratory Information System.

Excel | Pdf

Sample Reports
Normal and Abnormal sample reports are provided as references for report appearance.

Normal Reports | Abnormal Reports

SI Sample Reports
International System (SI) of Unit reports are provided for a limited number of tests. These reports are intended for international account use and are only available through MayoLINK accounts that have been defined to receive them.

SI Normal Reports | SI Abnormal Reports

Test Update Resources

Change Type Effective Date
Test Status - Test Resumed 2022-09-14
Test Status - Test Down 2022-07-01
Test Status - Test Resumed 2022-05-19
Test Status - Test Delay 2022-05-09
Test Status - Test Delay 2022-05-09